

# Shuichi Kishimoto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1946012/publications.pdf>

Version: 2024-02-01

15  
papers

332  
citations

1040056

9  
h-index

1058476

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

293  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. <i>Cancer</i> , 1989, 64, 1586-1594.	4.1	133
2	Role of Na <sup>+</sup> , K <sup>+</sup> -ATPase $\hat{1}\pm 1$ subunit in the intracellular accumulation of cisplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 84-90.	2.3	37
3	Cytotoxicity of cis-[[[(1R,2R)-1,2-Cyclohexanediamine-N,N']bis(myristato)]-platinum (II) Suspended in Lipiodol in a Newly Established Cisplatinresistant Rat Hepatoma Cell Line. <i>Japanese Journal of Cancer Research</i> , 2000, 91, 1326-1332.	1.7	30
4	Antitumor Effects of a Novel Lipophilic Platinum Complex (SM-11355) against a Slowly-Growing Rat Hepatic Tumor after Intra-Hepatic Arterial Administration.. <i>Biological and Pharmaceutical Bulletin</i> , 2000, 23, 344-348.	1.4	27
5	In Vitro Release of SM-11355, cis[[[(1R,2R)-1,2-Cyclohexanediamine-N,N']bis(myristato)] Platinum(II) Suspended in Lipiodol.. <i>Biological and Pharmaceutical Bulletin</i> , 2000, 23, 637-640.	1.4	27
6	Relation between Intracellular Accumulation and Cytotoxic Activity of cis-[[[(1R,2R)-1,2-Cyclohexanediamine-N,N']bis(myristato)]platinum(II) Suspended in Lipiodol. <i>Biological and Pharmaceutical Bulletin</i> , 2003, 26, 683-686.	1.4	16
7	Continuous Exposure to Low-Dose Cisplatin and Apoptosis. <i>Biological and Pharmaceutical Bulletin</i> , 2005, 28, 1954-1957.	1.4	16
8	In vitro Antitumor Activity, Intracellular Accumulation, and DNA Adduct Formation of cis-[[[(1R,2R)-1,2-Cyclohexanediamine-N,N']bis(myristato)]-platinum(II) Suspended in Lipiodol. <i>Cancer Research</i> , 2000, 91, 99-104.	1.7	10
9	Effects of insulin on CYP3A activity and nicardipine disposition in streptozotocin-induced diabetic rats. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 883-889.	2.4	9
10	In Vitro Cytotoxicity of cis[[[(1R,2R)-1,2-Cyclohexanediamine-N,N']bis(myristato)] Platinum(II) Suspended in Lipiodol in Rat Hepatoma AH-109A Cells and Human Tumor Cell Lines.. <i>Biological and Pharmaceutical Bulletin</i> , 2000, 23, 487-491.	1.4	6
11	Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells. <i>BioMetals</i> , 2016, 29, 1075-1083.	4.1	6
12	The Involvement of Pregnane X Receptor-regulated Pathways in the Antitumor Activity of Cisplatin. <i>Anticancer Research</i> , 2019, 39, 3601-3608.	1.1	6
13	Comparison of Pregnane X Receptor Antagonists for Enhancing the Antitumor Effect of Cisplatin. <i>Anticancer Research</i> , 2019, 39, 4749-4755.	1.1	3
14	Changes in the Expression of Various Transporters as Influencing Factors of Resistance to Cisplatin. , 2017, 37, 5477-5484.		3
15	Angiographic Evaluation of Vascular Damage in Rat Liver After Administration of Epirubicin or Miriplatin. <i>Anticancer Research</i> , 2018, 38, 247-251.	1.1	3